These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3172912)

  • 1. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 2. [The Spanish drug surveillance system].
    Laporte JR; Capellà D
    Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892
    [No Abstract]   [Full Text] [Related]  

  • 3. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
    Schindler B
    Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug surveillance: the concept, the need and methods].
    Moreno González A
    An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
    [No Abstract]   [Full Text] [Related]  

  • 5. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 6. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 7. [The 1990 drug law. Its implications for the clinical doctor].
    Castillo Pérez P; Gutiérrez López JF
    Med Clin (Barc); 1992 Feb; 98(7):263-9. PubMed ID: 1560703
    [No Abstract]   [Full Text] [Related]  

  • 8. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 9. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing risk in postmarketing surveillance.
    Cerrito PB; Cerrito JC
    J Biopharm Stat; 1991; 1(2):221-35. PubMed ID: 1844698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

  • 13. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 14. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 16. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 17. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 18. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 20. [Is establishment of causality in drug surveillance reliable?].
    Evreux JC
    Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.